Sugi Predict

Sugi Predict / Compounds / SCHEMBL569651

SCHEMBL569651

SCHEMBL569651

CC(C)(C)OC(=O)N1CC(O)(c2ccc(Br)cc2)C1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 4/20 0.55
▸ ROCK2 O75116 1/20 0.41
▸ FPR2 P25090 8/20 0.41
▸ FPR3 P25089 5/20 0.41
▸ USP30 Q70CQ3 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ ESRRB O95718 1/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ ESRRA P11474 1/20 0.38
▸ ESRRG P62508 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29691791 0.89 RORC (0.51) RORCROCK2FPR2FPR3USP30
SCHEMBL3695939 0.89 RORC (0.54) RORCFPR2FPR3USP30DRD2
SCHEMBL19462827 0.87 RORC (0.50) RORCFPR2FPR3USP30DRD2
SCHEMBL1430196 0.87 RORC (0.50) RORCFPR2FPR3USP30DRD2
SCHEMBL1199600 0.86 RORC (0.51) RORCFPR2FPR3JAK2JAK1
SCHEMBL31084071 0.85 MEN1 (0.52) RORCDRD2
SCHEMBL1310475 0.85 RORC (0.49) RORC
SCHEMBL18588038 0.85 RORC (0.41) RORCNR1H2DRD2GPR119
SCHEMBL1309072 0.85 RORC (0.51) RORCGPR119
SCHEMBL569652 0.84 RORC (0.54) RORCROCK2FPR2FPR3USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140371464-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2014-12-18 — — US claimed
US-12528802-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-20 — — US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 — — US disclosed
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 — — US disclosed
US-20220274982-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-01 — — US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 — — US disclosed
EP-4005638-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2022-06-01 — — EP disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 — — WO disclosed
CN-112047877-A Novel amide compound and use thereof 和记黄埔医药（上海）有限公司 2020-12-08 — — CN disclosed
WO-2020228823-A1 NOVEL AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2020-11-19 — — WO disclosed
WO-2013116236-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS LLC (US) 2013-08-08 — — WO disclosed
EP-2601190-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS AH USA 42 LLC (US) 2013-06-12 — — EP disclosed
US-8415310-B2 Isoxazoline derivatives as antiparasitic agents AH USA 42 LLC (US) 2013-04-09 — — US disclosed
US-8415310-B2 Isoxazoline derivatives as antiparasitic agents AH USA 42 LLC (US) 2013-04-09 — — US disclosed
US-8415310-B2 Isoxazoline derivatives as antiparasitic agents AH USA 42 LLC (US) 2013-04-09 — — US disclosed
US-20120035122-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2012-02-09 — — US disclosed
US-20120035122-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2012-02-09 — — US disclosed
WO-2012017359-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-02-09 — — WO disclosed
WO-2012017359-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-02-09 — — WO disclosed
US-20120035122-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 RORC 1116/4885ROCK2 3641/4885FPR2 298/4885
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R RORC 2294/4885ROCK2 1924/4885FPR2 714/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S RORC 992/4885ROCK2 3799/4885FPR2 426/4885
US-20120035122-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ADORA1, CYP3A7, RDX RORC 519/4885ROCK2 394/4885FPR2 1613/4885
US-20140371464-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS RDX, CYP2C9, CYP1A2 RORC 106/4885ROCK2 206/4885FPR2 2965/4885
US-12528802-B2 Heterocyclic compound GBA2, GBA1, GALC RORC 3846/4885ROCK2 2523/4885FPR2 1936/4885
US-20220274982-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC RORC 4397/4885ROCK2 1420/4885FPR2 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.